Document is current
Any future updates will be listed below
-
Authors
Huesa-Berral, Carlos https://orcid.org/0000-0003-2290-0176
Withrow, Julia D. https://orcid.org/0000-0001-6265-3355
Dawson, Robert J. https://orcid.org/0000-0002-0984-4088
Beekman, Chris https://orcid.org/0000-0002-0061-5473
Bolch, Wesley E. https://orcid.org/0000-0002-7175-9968
Paganetti, Harald https://orcid.org/0000-0002-6257-2413
Wehrenberg-Klee, Eric https://orcid.org/0000-0002-4712-3986
Bertolet, Alejandro https://orcid.org/0000-0002-9890-693X
-
Funding
Funding for this research was provided by:
Massachusetts General Hospital
- License Information
-
More Information
Article History
Received: 24 August 2023
Accepted: 8 December 2023
First Online: 29 December 2023
Declarations
:
: Eric Wehrenberg-Klee reports consulting fees from SIRTEX, Embolx, Avenge Biosciences, and Cytosite Bio. He has served on advisory boards for Delcath and Eisai. He is an IDMC member for Replimune. He receives clinical research funding from Boston Scientific. He is grant funded by NCI K08-245257.
